Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

Market Cap	23.48B
Revenue (ttm)	8.35B
Net Income (ttm)	1.10B
Shares Out	1.49B
EPS (ttm)	0.74
PE Ratio	21.26
Forward PE	13.49
Dividend	0.53 (3.37%)
Ex-Dividend Date	Oct 17, 2025

Volume	23,039,629
Average Volume	12,434,669
Open	15.54
Previous Close	15.54
Day's Range	15.46 - 15.91
52-Week Range	13.51 - 17.69
Beta	0.39
RSI	53.56
Earnings Date	Oct 25, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells medicines and related pharmaceuticals in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 10,958
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600535

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.